ASX:CU6 Clarity Pharmaceuticals (CU6) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Clarity Pharmaceuticals Stock (ASX:CU6) 30 days 90 days 365 days Advanced Chart Get CU6 alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationA$1.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia. Read More Receive CU6 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clarity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CU6 Stock News HeadlinesClarity confidence – and share price – up on bumper $203M institutional placementJuly 28 at 3:00 AM | msn.comClarity Pharmaceuticals Secures $203 Million in Institutional PlacementJuly 27 at 10:08 PM | tipranks.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.July 28 at 2:00 AM | Mode Mobile (Ad)Clarity Pharmaceuticals readies mega capital raisingJuly 27 at 9:59 PM | afr.comBroker says this ASX 200 biotech stock is a top buyJuly 25 at 11:43 AM | msn.comCU6 - Clarity Pharmaceuticals Ltd Valuation - MorningstarJuly 18, 2025 | morningstar.comMClarity Pharmaceuticals Issues Over 1.9 Million New SharesJuly 1, 2025 | tipranks.comClarity Pharmaceuticals Expands Capital with New Securities IssuanceJune 23, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:CU6 CIKN/A Webwww.claritypharmaceuticals.com Phone61 2 9209 4037FaxN/AEmployees41Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$42.32 million Net Margins-481.09% Pretax MarginN/A Return on Equity-42.46% Return on Assets-24.19% Debt Debt-to-Equity RatioN/A Current Ratio19.05 Quick Ratio13.19 Sales & Book Value Annual SalesA$11.51 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.51 per share Price / BookN/AMiscellaneous Outstanding Shares319,670,000Free FloatN/AMarket CapA$1.17 billion OptionableNot Optionable Beta1.58 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (ASX:CU6) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarity Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Clarity Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.